This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A second look at Relmada Therapeutics' novel NMDAR channel blocker, REL-1017, as monotherapy for the treatment of MDD and its P2 data
Ticker(s): RLMD, JNJ, AXSM, SAGEWho's the expert?
Institution: Private Practice, Los Gatos CA
- Private practice psychiatrist with research background, extensive industry collaboration, and frequent patient/peer educational activities.
- Currently manages 200 patients with depression, 50 patients with bipolar, and 25 patients with acute agitation per month.
- Previously served as an adjunct faculty member at the University of California at San Francisco Department of Psychiatry and the Stanford University Department of Psychiatry.
Interview GoalDiscussing the potential of REL-1017, Relmada Therapeutics' novel NMDAR channel blocker, as monotherapy for the treatment of MDD and reviewing the published Phase 2a data for REL-1017 as adjunctive treatment in MDD.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
